Orient Pharma Co (ROCO:4166) PE Ratio without NRI: 29.76 (As of Jul. 07, 2026) — 49% Below Median


ROCO:4166 Orient Pharma Co Ltd ROCO:4166
56 GF Score
Price NT$27.20
GF Value NT$45.09
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Orient Pharma Co PE Ratio without NRI?

Orient Pharma Co ROCO:4166 +5.02% 56 PE Ratio without NRI is 29.76 as of Jul. 07, 2026, which is 49% below its 10-year median of 58.74. GuruFocus rates ROCO:4166 with a GF Score™ of 56/100 and a GF Value™ of NT$45.09 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 654 Drug Manufacturers companies, Orient Pharma Co ranks worse than 63.3% on this metric.

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-07-07), Orient Pharma Co's share price is NT$27.20. Orient Pharma Co's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.91. Therefore, Orient Pharma Co's PE Ratio without NRI for today is 29.76.

During the past 13 years, Orient Pharma Co's highest PE Ratio without NRI was 129.67. The lowest was 25.88. And the median was 58.74.

Orient Pharma Co's EPS without NRI for the three months ended in Dec. 2025 was NT$0.38. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.91.

As of today (2026-07-07), Orient Pharma Co's share price is NT$27.20. Orient Pharma Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.90. Therefore, Orient Pharma Co's PE Ratio (TTM) for today is 30.39.

Good Sign:

Orient Pharma Co Ltd stock PE Ratio (=28.22) is close to 3-year low of 26.42.

During the past years, Orient Pharma Co's highest PE Ratio (TTM) was 163.24. The lowest was 26.42. And the median was 63.49.

Orient Pharma Co's EPS (Diluted) for the three months ended in Dec. 2025 was NT$0.38. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.90.

Orient Pharma Co's EPS (Basic) for the three months ended in Dec. 2025 was NT$0.38. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.90.


Orient Pharma Co  (ROCO:4166) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


Orient Pharma Co PE Ratio without NRI Related Terms


Orient Pharma Co PE Ratio without NRI Historical Data

* Premium members only.

The historical data trend for Orient Pharma Co's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orient Pharma Co PE Ratio without NRI Chart

Orient Pharma Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only At Loss At Loss 172.61 68.12 28.36

Orient Pharma Co Quarterly Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 68.12 65.19 93.40 42.23 28.36

ROCO:4166 vs ZTS, UTHR: PE Ratio without NRI Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Orient Pharma Co's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orient Pharma Co PE Ratio without NRI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orient Pharma Co's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Orient Pharma Co's PE Ratio without NRI falls into.


ROCO:4166
56GF Score
Orient Pharma Co Ltd ROCO:4166
PE Ratio without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orient Pharma Co PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

Orient Pharma Co's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=27.20/0.914
=29.76

Orient Pharma Co's Share Price of today is NT$27.20.
Orient Pharma Co's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.91.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio without NRI →
What does a PE Ratio without NRI of 29.76 mean?
Orient Pharma Co (ROCO:4166) has a PE Ratio without NRI of 29.76 as of Jul. 07, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Orient Pharma Co and its competitors. This is 49% below median its historical median of 58.74. Over the past decade, Orient Pharma Co's PE Ratio without NRI has ranged from 25.88 to 129.67. According to the industry distribution chart, Orient Pharma Co ranks #414 out of 654 companies in the Drug Manufacturers industry, placing it in the top 63.3%.
Is Orient Pharma Co's PE Ratio without NRI too high?
Orient Pharma Co's current PE Ratio without NRI of 29.76 is 49% below median its 10-year median of 58.74. Over the past 10 years, this metric has ranged from a low of 25.88 to a high of 129.67. The Drug Manufacturers industry median PE Ratio without NRI is 20.66. Orient Pharma Co's value of 29.76 is 44% above this industry median. Based on the distribution chart, Orient Pharma Co ranks #414 out of 654 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Orient Pharma Co has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Orient Pharma Co's PE Ratio without NRI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Orient Pharma Co ranks #414 out of 654 companies for PE Ratio without NRI. This places Orient Pharma Co in the lower half of its industry. The industry median PE Ratio without NRI is 20.66. Orient Pharma Co's value of 29.76 is 44% above this benchmark. Historically, Orient Pharma Co's own PE Ratio without NRI has ranged from 25.88 to 129.67 over the past decade. While the company's 10-year median is 58.74 vs. the industry median of 20.66, Orient Pharma Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Drug Manufacturers company?
The median PE Ratio without NRI among Drug Manufacturers companies is 20.66, based on 654 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orient Pharma Co's current PE Ratio without NRI of 29.76 is 44% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Orient Pharma Co and its competitors. For the Drug Manufacturers industry, the median PE Ratio without NRI is 20.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orient Pharma Co's current PE Ratio without NRI is 29.76, which is 49% below median its own 10-year median of 58.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orient Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Orient Pharma Co (ROCO:4166) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$45.09, compared to a current price of NT$27.20 — trading 39.7% below its estimated fair value. The current PE Ratio without NRI is 29.76, which is 49% below median its 10-year median of 58.74 and 44% above the Drug Manufacturers industry median of 20.66. Orient Pharma Co's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For Orient Pharma Co (ROCO:4166), the current PE Ratio without NRI is 29.76 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orient Pharma Co (ROCO:4166) Overvalued in 2026?

Based on GuruFocus' analysis, Orient Pharma Co stock appears to be undervalued. The current stock price of NT$27.20 is trading 39.7% below its estimated GF Value™ of NT$45.09. GuruFocus considers Orient Pharma Co to be Significantly Undervalued.

Key valuation signals for ROCO:4166:

  • PE Ratio without NRI: 29.76 (49% below median its 10-year median of 58.74)
  • GF Value™: NT$45.09 vs. price of NT$27.20 (39.7% below fair value)
  • GF Score™: 56/100 with 2 warning signs
  • Industry Position: 44% above the Drug Manufacturers median (#414 of 654)

No single metric tells the full story. See the ROCO:4166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Orient Pharma Co Business Description

Address No. 8, Kehu 1st Road, Huwei Town, Yunlin County, Central Science Park, Taipei, TWN, 106
Orient Pharma Co Ltd develops and manufactures pharmaceuticals. The Company mainly engages in the manufacturing, wholesale, and retail of western medicine and medical devices, as well as international trade. The company has two operating segments-Taiwan business segment- mainly engaged in developing the Taiwan pharmaceutical market and conducting related business activities and the other segment is Overseas business segment -mainly engaged in developing potential overseas pharmaceutical markets. Company's products include Cardiovascular drugs and Psychotropic drugs. The Group mainly operates in four regions: Taiwan, the United States, the Philippines, and China generating key revenue from Taiwan.
56GF Score

Get the complete analysis for ROCO:4166

PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$27.20
Price
NT$45.09
GF Value